A prospective phase II pilot study in non-endemic Sichuan reported strong early efficacy for tislelizumab added to induction chemotherapy in high-risk nasopharyngeal carcinoma, with 95.2% response rates and 80% event-free survival at 36 months at interim follow-up. The study frames immunotherapy as a feasible add-on earlier in the treatment sequence. Elsewhere in breast cancer, a randomized trial in Nature Communications reported that the oral CDK7 inhibitor samuraciclib plus fulvestrant improved clinical benefit rates in women with advanced HR-positive, HER2-negative disease previously treated with CDK4/6 inhibitors. Taken together, both reports highlight continued pivot toward targeting cell-cycle and transcriptional dependencies earlier or in combination regimens. For immuno-oncology engineering, a phase I trial of a CCL21-engineered dendritic cell vaccine combined with pembrolizumab increased T-cell infiltration in advanced lung cancer but did not produce objective tumor responses, underscoring the gap between immune trafficking and durable tumor control. A separate review also mapped the shifting glioblastoma pipeline toward biomarker-guided combinations. The combined set of findings reinforces an industry focus on sequencing: pairing targeted agents and checkpoint blockade with earlier induction settings or biomarker selection, while acknowledging that microenvironmental barriers still limit translation from immune biomarkers to response.